

IN THE U.S. PATENT AND TRADEMARK OFFICE

LARGE ENTITY TRANSMITTAL FORM

April 4, 2005

Transmitted herewith is an amendment in the above-identified application.

- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☐ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:


	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	30	-	44	=	0	\$50	\$0.00
INDEPENDENT	2	-	3	=	0	\$200	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$360	\$0.00
						TOTAL	\$0.00


- ☒ Petition for one (1) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$120.00 for the extension of time.
- ☐ No fee is required.
- ☒ Check(s) in the amount of \$120.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Mark J. Nuell, #36,623


DRN/RG/csm
0020-4872P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s)



PATENT
0020-4872P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Kyogo ITOH et al. Conf.: 3463
Appl. No.: 09/857,308 Group: 1642
Filed: June 1, 2001 Examiner: YAEN, C.
For: NOVEL TUMOR ANTIGEN PROTEIN ART-1 AND
TUMOR ANTIGEN PEPTIDES THEREOF

REPLY UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 4, 2005

Sir:

In reply to the Office Action of December 3, 2004, the due date having been extended one month, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

This reply includes:

Amended Claim Set;

Remarks; and

Parkhurst et al., *J. Immunology*, 157:2539-2548 (1996).

04/05/2005 SZEWDIE1 00000105 09857308

01 FC:1251

120.00 OP